Journal
CLINICAL AND EXPERIMENTAL DERMATOLOGY
Volume 34, Issue 5, Pages E202-E204Publisher
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1365-2230.2008.02991.x
Keywords
-
Categories
Ask authors/readers for more resources
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which is used to treat several cancers. Currently, experience with anti-VEGF treatment for psoriasis is limited, and no published reports on this use exist. We describe a patient with metastatic colon cancer and psoriasis who experienced complete remission of psoriasis during treatment with bevacizumab and combination chemotherapy without any other treatment for psoriasis. These data suggest that bevacizumab may be a promising therapeutic agent for the treatment of psoriasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available